News - Eylea

Filter

Current filters:

Eylea

Popular Filters

20 to 44 of 52 results

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

Positive Ph III results for Regeneron/Bayer's Eylea in mCNV

06-06-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany's Bayer (BAYN: DE) have…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

NICE "green light" for Bayer's Eylea as a treatment for wet AMD

31-05-2013

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…

BayerEuropeEyleaLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

Germany's IQWiG finds no proof of added benefit for Bayer's Eylea

22-03-2013

There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers

07-01-2013

After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN)…

BayerBiotechnologyEyleaMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneron

Bayer files for Japanese approval of Eylea for macular edema following CRVO

07-01-2013

German drug major Bayer(BAYN: DE) says its subsidiary Bayer Yakuhin has applied to the Japanese Ministry…

afliberceptAsia-PacificBayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronRegulationSanten Pharmaceuticals

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe

28-11-2012

Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

Eye disorders drug sales set to reach $23.8 billion in 2016, predicts Visiongain

18-10-2012

Total worldwide revenues from drugs to treat eye disorders will reach $23.8 billion in 2016, according…

EyleaGlobalMarkets & MarketingOphthalmicsPharmaceuticalRegeneron

EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP

24-09-2012

The European Medicines Agency last Friday issued a batch of recommendations relating to marketing authorization…

AlmirallBayerConstellaEuropeEyleaGastro-intestinalsIronwood PharmaceuticalsNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Santen to co-promote Bayer and Regeneron's Eylea in Japan

09-05-2012

German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals

Australia latest to approve Bayer's Eylea

08-03-2012

The Australian Therapeutic Goods Administration (TGA) has approved Eylea (aflibercept) Injection for…

Asia-PacificBayerEyleaOphthalmicsPharmaceuticalRegeneronRegulation

Bayer to file for EU approval of aflibercept for central retinal vein occlusion

21-02-2012

German drug major Bayer (BAY: DE) says that it will file for European approval of its macular edema treatment…

afliberceptBayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulationResearch

Regeneron ups Eylea forecast, posts 2011 results

14-02-2012

USA-based biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares leap 12% to $114.10 in…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneronResearch

Regeneron and Bayer’s Eylea backed by thought leaders for DME

13-02-2012

Based on clinical data and the opinions of interviewed thought leaders by health care advisory firm Decision…

AllerganBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsOzurdexPharmaceuticalRegeneron

20 to 44 of 52 results

Back to top